Mereo BioPharma (MREO) Payables (2017 - 2026)

Mereo BioPharma (MREO) has reported Payables for 10 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 1.49% year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was $1.1 million, a 1.49% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 83.29% from the prior year.
• Payables was $1.1 million for Q2 2026 at Mereo BioPharma, down from $3.2 million in the prior quarter.
• Over five years, Payables peaked at $16.6 million in Q4 2022 and troughed at $879000.0 in Q3 2025.
• A 5-year average of $5.1 million and a median of $3.4 million in 2026 frame the typical range for Payables.
• Across the five-year window, Payables jumped 393.14% in 2022 and sank 87.96% in 2025, its largest moves.
• Over 5 years, Payables stood at $16.6 million in 2022, then sank by 85.88% to $2.3 million in 2023, then jumped by 239.94% to $8.0 million in 2024, then plunged by 83.29% to $1.3 million in 2025, then fell by 15.9% to $1.1 million in 2026.
• The last three Payables figures came in at $1.1 million (Q2 2026), $3.2 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.